The TRAIN-HEART consortium, funded by the European Commission (2019-2023), is made up to train a league of 15 promising fellows that harness novel insights in the pathogenesis of ischemic heart failure, study the therapeutic potential of existing RNA therapeutics and improve its efficacy by the design of novel drug delivery systems.
TRAIN-HEART brings together leading academic teams and (biotech) companies covering various disciplines ranging from fundamental research to clinical pharmacology and gene therapy to drug delivery applications, have teamed up in the European Union.
The TRAIN-HEART network aims to gain viable insight in the pathogenesis of ischemic heart failure which will serve as a basis for drug discovery and drug delivery efforts that aim to therapeutically target specific molecules and mechanisms within cardiomyocytes for the treatment of ischemic heart failure.
If you have any questions you can fill in the form or mail us directly: firstname.lastname@example.org.
The mission of the ISHR is to promote the discovery and dissemination of knowledge in the cardiovascular sciences on a world-wide basis. Membership is open to any individual (with or without MD or PhD) who is actively interested in any aspect of experimental or clinical research in the cardiovascular system. Several PIs in the TRAIN-HEART network are involved in ISHR either as board member/president or executive organisation member. We are glad that the TRAIN-HEART network was so well represented at this important conference.
Thu, 08 September